Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder cancer, positioning the Big Pharma to file for approval of an ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 in ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

Pfizer’s GLP-1 weight management treatment Xianweiying is available for pre-order in China, ​a Reuters check on a local e-commerce ‌platform showed, ramping up competition with rivals in a market ...

Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 ...